Skip to content

Comparison of Effect of Guduchyadi Yoga and Navak Guggulu in the management of Medoroga (Dyslipidaemia)

Comparative clinical study to evaluate the efficacy of Guduchyadi Yoga with Navak Guggulu in Medoroga w.s.r. Dyslipidaemia- a Randomized controlled trial - nil

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/079864
Enrollment
60
Registered
2025-02-03
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E789- Disorder of lipoprotein metabolism, unspecified

Interventions

None listed

Sponsors

Chaudhary brahm prakash ayurved charak sansthan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a. Already Diagnosed cases of Dyslipidaemia based on investigation within 1 month of period. b. Subjects with any one or more Lakshana of Medoroga. c. Subjects with any one or more of the following parameter - Total Cholesterol above 200mg/dl and upto 400mg/dl, Triglycerides above 150 mg/dl and upto 300 mg/dl or HDL below 40mg/dl and upto 20 mg/dl or LDL above 100mg/dl and upto 200 mg/dl or VLDL above 30mg/dl to 60 mg/dl. d. Subjects between the age group of 21-60 years of either sex. e. Subjects who are ready to give consent with firm home address and contact no. which is readily accessible during coarse of trial.

Exclusion criteria

Exclusion criteria: a. Subjects with total cholesterol above 400mg/dl or Triglycerides above 300 mg/dl or LDL cholesterol above 200mg/dl or HDL cholesterol below 20mg/dl, VLDL above 60 mg/dl. b. Subjects having Insulin dependent Diabetes Mallitus and uncontrolled DMT2 even after using OHA. c. Subjects with uncontrolled Hypertension -BP greater than 150/90 mm of Hg. d. Subjects having major systemic illness except patients of obesity, controlled DMT2, controlled patients of Hypertension. e. Subject below 21 years and above 60 years of age. f. History of adverse reaction to any trial drug or their ingredients. g. Pregnant females and lactating mothers. h. Subjects who are already registered in any other research project. i. Subjects who are not willing for the trial.

Design outcomes

Primary

MeasureTime frame
Reduction in the hematological parameters of dyslipidaemia Total cholesterol: Levels below 200 mg/dL Triglycerides: levels below 150 mg/dL LDL cholesterol: Levels below 100 mg/dL HDL cholesterol: Levels above 40 mg/dL in men and above 50 mg/dL in women VLDL cholesterol: levels below 30 mg/dL Timepoint: 90 days

Secondary

MeasureTime frame
Improvement in Clinical features of Medoroga a) Kshudra Shwasa (Breathlessness) b) Trishna (Polydipsia) c) Nidraadhikya (Excessive sleep) d) Kshudha Atimatra (Excessive hunger) e) Swedadhikya (Excessive sweating) f) Daurgandhya (Bad odour of body) g) Alpa Prana (Fatigue)Timepoint: 90 days

Countries

India

Contacts

Public ContactProf Dr N R Singh

Chaudhary brahm prakash ayurved charak sansthan

naimishraj@yahoo.com9560659728

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026